Cayd Biotech
卡尤迪生物
Cayd Biotech (卡尤迪生物) is a molecular diagnostics company in FreeS Fund's portfolio, known for developing nucleic acid rapid-testing systems. In 2020, the company received approval for what FreeS Fund described as China's first approved rapid nucleic acid testing system, deploying its core molecular diagnostic technology for COVID-19 PCR testing during the pandemic . FreeS Fund has listed Cayd among its high-growth portfolio companies in multiple portfolio reviews from 2021 through 2023 . The company's Chinese name appears alongside biotech peers such as NewGen Therapeutics (新格元) and Yanming Biotech (炎明生物) in FreeS Fund's biomedical coverage . elsewhere's corpus does not contain more recent operational or financing details beyond these portfolio mentions.
AI-generated — may contain errors, please verify.
Coverage
Trends 2023 | FreeS Fund China-US Venture Summit Opens Registration
Three livestreams and five offline salons — come join us!
峰瑞资本·FreeS Fund Earns Ten Honors from Zero2IPO, PEDaily, ChinaVenture & GEW, CVCRI, ChinaRong360, Wanbang RB, and Lancha Consumer | FreeS Matters
Continuously hiring investors
峰瑞资本·FreeS Fund Wins 12 Awards, Thanks to Recognition from 36Kr, ChinaVenture, FOFWEEKLY, Cyzone, and 21st Century Business Herald | FreeS Fund
Continuously Hiring Investors
峰瑞资本·Celebrating Six Years, Looking Forward to More Upward-Minded Partners Joining Us | FreeS Fund
Do what's right, not what's easy.
峰瑞资本·FreeS Fund 2021 Outlook ② | Three Trends in Biomedical Innovation
The Biopharma Industry Enters the "Three Fast" Era
峰瑞资本·
